SCHEMBL4314947

SCHEMBL4314947

CC(C)C(=O)Nc1ccc(C(=O)Nc2ccccc2/C=C/c2n[nH]c3ccccc23)s1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 7/20 0.41
EPHB3 P54753 1/20 0.39
YTHDC1 Q96MU7 1/20 0.36
AURKA O14965 2/20 0.36
AURKB Q96GD4 2/20 0.36
FLT3 P36888 3/20 0.35
CCNA2 P20248 1/20 0.35
CDK2 P24941 1/20 0.35
CCNA1 P78396 1/20 0.35
ITK Q08881 2/20 0.34
CHEK1 O14757 2/20 0.34
BMPR1B O00238 1/20 0.34
PLK4 O00444 1/20 0.34
STK25 O00506 1/20 0.34
CIT O14578 1/20 0.34
RIOK3 O14730 1/20 0.34
IKBKB O14920 1/20 0.34
GAK O14976 1/20 0.34
DCLK1 O15075 1/20 0.34
CHUK O15111 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4314953 1.00 KDR (0.41) KDREPHB3YTHDC1AURKAAURKB
SCHEMBL4313552 0.90 KDR (0.42) KDREPHB3YTHDC1AURKAAURKB
SCHEMBL4313556 0.90 KDR (0.42) KDREPHB3YTHDC1AURKAAURKB
SCHEMBL27711635 0.86 KDR (0.49) KDREPHB3YTHDC1AURKAAURKB
SCHEMBL4309552 0.86 KDR (0.49) KDREPHB3YTHDC1AURKAAURKB
SCHEMBL4322679 0.86 ALDH1A1 (0.42) KDREPHB3AURKAAURKBSTK33
SCHEMBL4322671 0.86 ALDH1A1 (0.42) KDREPHB3AURKAAURKBSTK33
SCHEMBL4313824 0.84 SMN1; SMN2 (0.46) KDREPHB3AURKAAURKBCHEK1
SCHEMBL4313818 0.84 SMN1; SMN2 (0.46) KDREPHB3AURKAAURKBCHEK1
SCHEMBL4319176 0.84 KDR (0.51) KDREPHB3YTHDC1AURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 KDR 75/4885EPHB3 3547/4885YTHDC1 4310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.